Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 26th at 6:00 PM EST.

To Purchase # 8904SC

8904SC 10 µg (With Carrier)
8904SF 10 µg (Carrier Free)
8904LC 50 µg (With Carrier)
8904LF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IL-6 (hIL-6) Val30-Met212 (Accession #NM_000600) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-6. All lots are greater than 98% pure.


Molecular Formula:

Based on amino acid sequencing, greater than 60% of recombinant hIL-6 has a Met on the amino-terminal Val30 (sequence of MVPPG) and has a calculated MW of 20,943. The remainder starts at pro 32 (sequence of PPGED) or Pro33 (sequence of PGEDS). DTT-reduced protein migrates as a 23 kDa polypeptide and non-reduced protein migrates as a 22 kDa polypeptide due to intramolecular cystines.


Bioactivity:

The bioactivity of recombinant hIL-6 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 0.2-0.7 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIL-6.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, and others. IL-6 in concert with TGFβ is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/Erk MAP kinase cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3).The IL-6/soluble IL-6Rα complex can then activate the gp130 signaling pathway on cells that express gp130 but not IL-6Rα (3). IL-6, through increasing expression of proangiogenic VEGF, may contribute to metastatic breast cancer (5).


1.  Heinrich, P.C. et al. (1998) Biochem J 334 ( Pt 2), 297-314.

2.  Heinrich, P.C. et al. (1998) Z Ernahrungswiss 37 Suppl 1, 43-9.

3.  Jones, S.A. (2005) J Immunol 175, 3463-8.

4.  Jenkins, B.J. et al. (2004) Mol Cell Biol 24, 1453-63.

5.  Hong, D.S. et al. (2007) Cancer 110, 1911-28.


Entrez-Gene Id 3569
Swiss-Prot Acc. P05231


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.